EvaluatePharma USA, Inc. Welcomed Into Boston Biotech Community by Mayor Menino
BOSTON, November 11, 2010 /PRNewswire/ -- EvaluatePharma USA, Inc. the online analysis service for the global biotechnology and pharmaceutical sector, was welcomed into Boston's biotech community today by Mayor Menino at the opening of their new office in Boston, the #1 life sciences cluster in the US.
Senior Vice President Debbie Paul said, "EvaluatePharma USA are very excited to be joining the Boston biotech community with the opening of our new office at Broad Street. Many of our clients are based in Boston and we will now be able to work more closely with the biotech community, supporting them with innovative products and services designed to help the commercialization of their products."
Commenting at the opening ceremony, Dr. Jonathan de Pass, CEO and Founder said "We are very grateful to Mayor Menino and the LifeTech programme for their help and support in the opening of this new office. EvaluatePharma is committed to developing new products and services that continue to support the biotech community such as the launch of our new service Partnering Opportunities. By registering their licensing assets with our Partnering Opportunities the biotech community can reach our global audience of business development and licensing professionals across the world's leading pharma companies."
EvaluatePharma's Partnering Opportunities is a new free service that allows potential partners to see the latest opportunities from the biotech community in their commercial context alongside EvaluatePharma's industry analysis, including product portfolios, company financials and reference deal terms.
Founded in 1996 by Dr. Jonathan de Pass, a former top-ranked Pharmaceutical analyst in the City of London, EvaluatePharma(R) provides proprietary insights into the commercial and financial prospects of the pharma and biotech industry and was the first company to provide reliable consensus forecasts of global drug sales. Analyses range from total market sales trends and therapeutic overviews to individual company financial performance and product progress.
EvaluatePharma's client base includes the top global pharma and biotech companies, the investment banking community and the leading global management consulting firms.
Notes to editors
The research company EvaluatePharma was the first to supply reliable consensus forecasts of global drug sales and now provides standardised worldwide financial and forecast models with consensus product sales forecasts to 2016, data on R&D pipelines, licensing deals, patent risk and M&A activity. Launched in 2007, EvaluatePharma(R)Alpha offers a Net Present Value (NPV) valuation service quantifying market events and the impact on product, portfolio and company valuation including the daily online news service EP Vantage(R).
EvaluatePharma(R), EvaluatePharma(R)Alpha, and EP Vantage(R) are services of EvaluatePharma Ltd, headquartered in London, England. In North America, EvaluatePharma Ltd is represented by
EvaluatePharma USA, Inc. http://www.evaluatepharma.com Contact: Debbie Paul Senior Vice President, North America T: +1-866-806-1309 E: email@example.com EvaluatePharma USA, Inc. 15 Broad Street, Suite 401 Boston, MA 02109 USA Andrew Beaven Marketing Director, EvaluatePharma Ltd T: +44(0)20-7539-1818 E: firstname.lastname@example.org EvaluatePharma Ltd 11-29 Fashion Street London E1 6PX United Kingdom
SOURCE EvaluatePharma Ltd